Suppr超能文献

喀麦隆的黄热病防控:我们目前的状况及未来走向?

Yellow fever control in Cameroon: where are we now and where are we going?

作者信息

Wiysonge Charles Shey, Nomo Emmanuel, Mawo Jeanne, Ofal James, Mimbouga Julienne, Ticha Johnson, Ndumbe Peter M

机构信息

Central Technical Group, Expanded Programme on Immunisation, Ministry of Public Health, Yaoundé, Cameroon.

出版信息

BMC Med. 2008 Feb 8;6:3. doi: 10.1186/1741-7015-6-3.

Abstract

BACKGROUND

Cameroon is one of 12 African countries that bear most of the global burden of yellow fever. In 2002 the country developed a five-year strategic plan for yellow fever control, which included strategies for prevention as well as rapid detection and response to outbreaks when they occur. We have used data collected by the national Expanded Programme on Immunisation to assess the progress made and challenges faced during the first four years of implementing the plan.

METHODS

In January 2003, case-based surveillance of suspected yellow fever cases was instituted in the whole country. A year later, yellow fever immunisation at nine months of age (the same age as routine measles immunisation) was introduced. Supplementary immunisation activities (SIAs), both preventive and in response to outbreaks, also formed an integral part of the yellow fever control plan. Each level of the national health system makes a synthesis of its activities and sends this to the next higher level at defined regular intervals; monthly for routine data and daily for SIAs.

RESULTS

From 2004 to 2006 the national routine yellow fever vaccination coverage rose from 58.7% to 72.2%. In addition, the country achieved parity between yellow fever and measles vaccination coverage in 2005 and has since maintained this performance level. The number of suspected yellow fever cases in the country increased from 156 in 2003 to 859 in 2006, and the proportion of districts that reported at least one suspected yellow fever case per year increased from 31.4% to 68.2%, respectively. Blood specimens were collected from all suspected cases (within 14 days of onset of symptoms) and tested at a central laboratory for yellow fever IgM antibodies; leading to confirmation of yellow fever outbreaks in the health districts of Bafia, Méri and Ntui in 2003, Ngaoundéré Rural in 2004, Yoko in 2005 and Messamena in 2006. Owing to constraints in rapidly mobilising the necessary resources, reactive SIAs were only conducted in Bafia and Méri several months after confirmation of the outbreak. In both districts, a total of 60,083 people (representing 88.2% of the 68,103 targeted) were vaccinated. Owing to the same constraints, SIAs were not conducted promptly in response to the outbreaks in Ntui, Ngaoundéré Rural, Yoko and Messamena. However, these four and two other health districts at high risk of yellow fever outbreaks (i.e. Maroua Urban and Ngaoundéré Urban) conducted preventive SIAs in November 2006, vaccinating a total of 752,195 people (92.8% of target population). In both the reactive and preventive SIAs, the mean wastage rates for vaccines and injection material were less than 5% and there was no report of a serious adverse event following immunisation.

CONCLUSION

Amidst other competing health priorities, over the past four years Cameroon has successfully planned and implemented evidence-based strategies for preventing yellow fever outbreaks and for detecting and responding to the outbreaks when they occur. In order to sustain these initial successes, the country will have to attain and sustain high routine vaccination coverage in each successive birth cohort in every district. This would require fostering and sustaining high-level political commitment, improving the planning and monitoring of immunisation services at all levels, adequate community mobilisation, and efficient coordination of current and future immunisation partners.

摘要

背景

喀麦隆是承担全球大部分黄热病负担的12个非洲国家之一。2002年,该国制定了一项为期五年的黄热病防控战略计划,其中包括预防策略以及疫情发生时的快速检测和应对措施。我们利用国家扩大免疫规划收集的数据,评估了该计划实施头四年所取得的进展和面临的挑战。

方法

2003年1月,在全国范围内建立了基于病例的疑似黄热病病例监测体系。一年后,引入了9月龄(与常规麻疹免疫接种年龄相同)的黄热病免疫接种。补充免疫活动,包括预防性活动和针对疫情的活动,也是黄热病防控计划的一个组成部分。国家卫生系统的每个层级都会对其活动进行汇总,并在规定的定期时间将其上报给上一级;常规数据每月上报,补充免疫活动数据每日上报。

结果

2004年至2006年,全国常规黄热病疫苗接种覆盖率从58.7%升至72.2%。此外,该国在2005年实现了黄热病和麻疹疫苗接种覆盖率持平,并自此保持这一水平。该国疑似黄热病病例数从2003年的156例增至2006年的859例,每年至少报告1例疑似黄热病病例的地区比例分别从31.4%增至68.2%。从所有疑似病例(症状出现后14天内)采集血样,并在中央实验室检测黄热病IgM抗体;从而确认了2003年巴菲亚、梅里和恩图伊卫生区、2004年恩冈代雷农村、2005年约科以及2006年梅萨梅纳的黄热病疫情。由于在迅速调集必要资源方面存在限制,在疫情确认数月后,仅在巴菲亚和梅里开展了应急补充免疫活动。在这两个地区,共有60083人(占68103名目标人群的88.2%)接种了疫苗。由于同样的限制,在恩图伊、恩冈代雷农村、约科和梅萨梅纳疫情发生后,补充免疫活动未能及时开展。不过,这四个卫生区以及另外两个黄热病疫情高风险卫生区(即马鲁阿市区和恩冈代雷市区)在2006年11月开展了预防性补充免疫活动,共为752195人(占目标人群的92.8%)接种了疫苗。在应急和预防性补充免疫活动中,疫苗和注射材料的平均损耗率均低于5%,且未报告免疫接种后出现严重不良事件。

结论

在其他卫生重点工作相互竞争的情况下,喀麦隆在过去四年成功规划并实施了基于证据的策略,以预防黄热病疫情,并在疫情发生时进行检测和应对。为了维持这些初步成果,该国必须在每个地区的每个连续出生队列中实现并维持高常规疫苗接种覆盖率。这将需要培养并维持高层级的政治承诺,改善各级免疫服务的规划和监测,充分动员社区,以及有效协调当前和未来的免疫合作伙伴。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/866b/2268705/f951982391c8/1741-7015-6-3-1.jpg

相似文献

1
Yellow fever control in Cameroon: where are we now and where are we going?
BMC Med. 2008 Feb 8;6:3. doi: 10.1186/1741-7015-6-3.
3
Changing epidemiology of yellow fever virus in Oyo State, Nigeria.
BMC Public Health. 2022 Mar 8;22(1):467. doi: 10.1186/s12889-022-12871-0.
8
Is the absence or intermittent YF vaccination the major contributor to its persistent outbreaks in eastern Africa?
Biochem Biophys Res Commun. 2017 Oct 28;492(4):548-557. doi: 10.1016/j.bbrc.2017.01.079. Epub 2017 Jan 18.
9
The resurgence of yellow fever outbreaks in Nigeria: a 2-year review 2017-2019.
BMC Infect Dis. 2021 Oct 11;21(1):1054. doi: 10.1186/s12879-021-06727-y.

引用本文的文献

2
Development and standardization of a COVID-19 Vaccination Anxiety scale for Adult Urban Indian Population (CVAS-A).
Hum Vaccin Immunother. 2022 Nov 30;18(5):2059307. doi: 10.1080/21645515.2022.2059307. Epub 2022 Apr 20.
3
The incidence and mortality of yellow fever in Africa: a systematic review and meta-analysis.
BMC Infect Dis. 2021 Oct 23;21(1):1089. doi: 10.1186/s12879-021-06728-x.
4
Vaccine hesitancy in the era of COVID-19: could lessons from the past help in divining the future?
Hum Vaccin Immunother. 2022 Dec 31;18(1):1-3. doi: 10.1080/21645515.2021.1893062. Epub 2021 Mar 8.
5
Seroprevalence of dengue virus among children presenting with febrile illness in some public health facilities in Cameroon.
Pan Afr Med J. 2018 Nov 13;31:177. doi: 10.11604/pamj.2018.31.177.16390. eCollection 2018.
6
Global yellow fever vaccination coverage from 1970 to 2016: an adjusted retrospective analysis.
Lancet Infect Dis. 2017 Nov;17(11):1209-1217. doi: 10.1016/S1473-3099(17)30419-X. Epub 2017 Aug 16.
7
Unexplained haemorrhagic fever in Rural Ethiopia.
Pan Afr Med J. 2017 May 28;27(Suppl 1):3. doi: 10.11604/pamj.supp.2017.27.1.12567. eCollection 2017.

本文引用的文献

1
THE USE OF YELLOW FEVER VIRUS MODIFIED BY IN VITRO CULTIVATION FOR HUMAN IMMUNIZATION.
J Exp Med. 1937 May 31;65(6):787-800. doi: 10.1084/jem.65.6.787.
2
Acute viscerotropic disease following vaccination against yellow fever.
Trans R Soc Trop Med Hyg. 2007 Oct;101(10):967-71. doi: 10.1016/j.trstmh.2007.06.013. Epub 2007 Jul 31.
3
An evaluation of infant immunization in Africa: is a transformation in progress?
Bull World Health Organ. 2007 Jun;85(6):449-57. doi: 10.2471/blt.06.031526.
4
Effectiveness of the oral polio vaccine and prospects for global eradication of polio.
Trop Doct. 2007 Apr;37(2):125-6. doi: 10.1177/004947550703700233.
7
Neurological adverse events temporally associated to mass vaccination against yellow fever in Juiz de Fora, Brazil, 1999-2005.
Vaccine. 2007 Apr 20;25(16):3124-8. doi: 10.1016/j.vaccine.2007.01.078. Epub 2007 Jan 30.
8
Has the 2005 measles mortality reduction goal been achieved? A natural history modelling study.
Lancet. 2007 Jan 20;369(9557):191-200. doi: 10.1016/S0140-6736(07)60107-X.
9
Yellow fever situation in Africa and South America, 2005.
Wkly Epidemiol Rec. 2006 Aug 18;81(33):317-24.
10
Yellow fever: a disease that has yet to be conquered.
Annu Rev Entomol. 2007;52:209-29. doi: 10.1146/annurev.ento.52.110405.091454.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验